

8. A pharmaceutical composition comprising an effective amount of a compound of general formula 1 according to claim 4 or a physiologically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.

9. A pharmaceutical composition according to claim 5, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

10. A pharmaceutical composition according to claim 6, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

11. A pharmaceutical composition according to claim 7, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

12. A pharmaceutical composition according to claim 8, further comprising an additional active substance selected from betamimetics, antiallergics, PAF antagonists, PDE-IV inhibitors, leukotriene antagonists, p38 kinase inhibitors, EGFR kinase inhibitors, and corticosteroids.

13. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 1.

Ex-A

Carrel

14. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 2.

15. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 3.

16. A method for treatment of a disease which is responsive to an anticholinergic agent in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 4.

17. A method for treatment of a disease selected from asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders,~~ ^{and} spasms in the gastrointestinal tract, spasms in the urinary tract, ~~and menstrual pain,~~ in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 1.

18. A method for treatment of a disease selected from asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders,~~ ^{and} spasms in the gastrointestinal tract, spasms in the urinary tract, ~~and menstrual pain,~~ in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 2.

19. A method for treatment of a disease selected from asthma, COPD, ~~vagally induced sinus bradycardia, heart rhythm disorders,~~ ^{and} spasms in the gastrointestinal tract, spasms in the urinary tract, ~~and menstrual pain,~~ in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 3.

20. A method for treatment of a disease selected from asthma, COPD, ~~vagally induced~~^{and} ~~sinus bradycardia, heart rhythm disorders,~~ spasms in the gastrointestinal tract, spasms in the urinary tract, ~~and menstrual pain,~~ in a patient, the method comprising administering to the patient in need thereof an effective amount of a compound of general formula 1 according to claim 4.

Ex. A